Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis.
- Resource Type
- Academic Journal
- Authors
- Boucher A; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France. Electronic address: aboucher@ch-tourcoing.fr.; Pradier M; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Lafondesmurs B; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Thill P; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Patoz P; Laboratoire de Microbiologie, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Blondiaux N; Laboratoire de Microbiologie, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Joulie D; Service de Chirurgie Orthopédique et Traumatologique, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.; Hennart B; Service de Toxicologie-Génopathies, Centre Hospitalier Universitaire de Lille, F-59000, Lille, France.; Robineau O; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France; Université de Lille, ULR 2694 - METRICS : Évaluation des technologies de santé et des pratiques médicales, F-59000, Lille, France.; Senneville E; Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France; Université de Lille, ULR 2694 - METRICS : Évaluation des technologies de santé et des pratiques médicales, F-59000, Lille, France.
- Source
- Publisher: Elsevier Masson Country of Publication: France NLM ID: 101775152 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-9919 (Electronic) Linking ISSN: 26669919 NLM ISO Abbreviation: Infect Dis Now Subsets: MEDLINE
- Subject
- Language
- English
Objectives: We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.
Patients and Methods: Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.
Results: Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.
Conclusions: In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Masson SAS. All rights reserved.)